ATE228856T1 - Mittel für die steuerung von der zellaktivität - Google Patents
Mittel für die steuerung von der zellaktivitätInfo
- Publication number
- ATE228856T1 ATE228856T1 AT94909262T AT94909262T ATE228856T1 AT E228856 T1 ATE228856 T1 AT E228856T1 AT 94909262 T AT94909262 T AT 94909262T AT 94909262 T AT94909262 T AT 94909262T AT E228856 T1 ATE228856 T1 AT E228856T1
- Authority
- AT
- Austria
- Prior art keywords
- domain
- agent
- cell
- endosome
- cell activity
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Physics & Mathematics (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB939305735A GB9305735D0 (en) | 1993-03-19 | 1993-03-19 | Novel agent for controlling cell activity |
PCT/GB1994/000558 WO1994021300A2 (en) | 1993-03-19 | 1994-03-18 | Novel agent for controlling cell activity |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE228856T1 true ATE228856T1 (de) | 2002-12-15 |
Family
ID=10732382
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT94909262T ATE228856T1 (de) | 1993-03-19 | 1994-03-18 | Mittel für die steuerung von der zellaktivität |
Country Status (25)
Country | Link |
---|---|
US (1) | US20080070278A1 (de) |
EP (1) | EP0689459B1 (de) |
JP (2) | JP4300265B2 (de) |
KR (1) | KR960700756A (de) |
CN (1) | CN1195551C (de) |
AT (1) | ATE228856T1 (de) |
AU (1) | AU671203C (de) |
BR (1) | BR9406232A (de) |
CA (1) | CA2158647A1 (de) |
CZ (1) | CZ242695A3 (de) |
DE (1) | DE69431832T2 (de) |
DK (1) | DK0689459T3 (de) |
ES (1) | ES2183836T3 (de) |
FI (1) | FI954390A (de) |
GB (1) | GB9305735D0 (de) |
HU (1) | HU217220B (de) |
IL (1) | IL109045A0 (de) |
IN (1) | IN178499B (de) |
NO (1) | NO953643L (de) |
NZ (1) | NZ262484A (de) |
PL (1) | PL178895B1 (de) |
PT (1) | PT689459E (de) |
SG (1) | SG73411A1 (de) |
SK (1) | SK115595A3 (de) |
WO (1) | WO1994021300A2 (de) |
Families Citing this family (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9305735D0 (en) * | 1993-03-19 | 1993-05-05 | North John R | Novel agent for controlling cell activity |
AU695623B2 (en) | 1994-05-31 | 1998-08-20 | Allergan, Inc. | Modification of clostridial toxins for use as transport proteins |
GB9410871D0 (en) | 1994-05-31 | 1994-07-20 | Imperial College | Modification of tetanus toxin for use as a transport protein |
GB9508204D0 (en) | 1995-04-21 | 1995-06-07 | Speywood Lab Ltd | A novel agent able to modify peripheral afferent function |
GB9617671D0 (en) | 1996-08-23 | 1996-10-02 | Microbiological Res Authority | Recombinant toxin fragments |
US7192596B2 (en) | 1996-08-23 | 2007-03-20 | The Health Protection Agency Ipsen Limited | Recombinant toxin fragments |
US8012491B2 (en) | 1996-08-23 | 2011-09-06 | Syntaxin, Ltd. | Recombinant toxin fragments |
GB9721189D0 (en) | 1997-10-08 | 1997-12-03 | Speywood Lab The Limited | Analgesic conjugates |
PL201879B1 (pl) * | 1998-05-13 | 2009-05-29 | Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh | Białko hybrydowe i jego zastosowanie |
US20040071736A1 (en) | 1998-08-25 | 2004-04-15 | Health Protection Agency | Methods and compounds for the treatment of mucus hypersecretion |
GB9818548D0 (en) | 1998-08-25 | 1998-10-21 | Microbiological Res Authority | Treatment of mucas hypersecretion |
GB9907429D0 (en) | 1999-03-31 | 1999-05-26 | Microbiological Res Authority | Modulation of C-fibre activity |
DE60032367T3 (de) | 1999-08-25 | 2011-03-10 | Allergan, Inc., Irvine | Aktivierbare rekombinante neurotoxine |
US20080038274A1 (en) | 1999-09-23 | 2008-02-14 | Foster Keith A | Inhibition of secretion from non-neuronal cells |
GB9922554D0 (en) * | 1999-09-23 | 1999-11-24 | Microbiological Res Authority | Inhibition of secretion from non-neuronal cells |
US6265379B1 (en) | 1999-10-13 | 2001-07-24 | Allergan Sales, Inc. | Method for treating otic disorders |
GB9926875D0 (en) * | 1999-11-12 | 2000-01-12 | Microbiological Research Agenc | Use of lytic toxins and toxin conjugates |
US6337075B1 (en) | 2000-01-11 | 2002-01-08 | Allergan Sales, Inc. | Methods for treating diabetes |
US7138127B1 (en) | 2000-01-19 | 2006-11-21 | Allergan, Inc. | Clostridial toxin derivatives and methods for treating pain |
US6773711B2 (en) | 2000-02-15 | 2004-08-10 | Allergan, Inc. | Botulinum toxin therapy for Hashimoto's thyroiditis |
US6524580B1 (en) | 2000-02-15 | 2003-02-25 | Allergan Sales, Inc. | Method for treating thyroid disorders |
US6328977B1 (en) | 2000-02-22 | 2001-12-11 | Allergan Sales, Inc. | Method for treating hyperparathyroidism |
US6565870B1 (en) | 2000-04-28 | 2003-05-20 | Allergan, Inc. | Methods for treating bone tumors |
GB0216865D0 (en) * | 2002-07-19 | 2002-08-28 | Microbiological Res Authority | Targetted agents for nerve regeneration |
US20060153876A1 (en) * | 2003-02-24 | 2006-07-13 | Ira Sanders | Cell membrane translocation of regulated snare inhibitors, compositions therefor, and methods for treatment of disease |
GB0321344D0 (en) * | 2003-09-11 | 2003-10-15 | Health Prot Agency | Re-targeted toxin conjugates |
DK1531647T3 (da) * | 2003-11-14 | 2010-05-10 | Starhome Gmbh | Styring af indkommende opkald til roamende abonnenter i et cellulært mobiltelefonnet |
ATE416191T1 (de) | 2004-09-01 | 2008-12-15 | Allergan Inc | Abbaubare clostridientoxine |
US8778634B2 (en) | 2004-12-01 | 2014-07-15 | Syntaxin, Ltd. | Non-cytotoxic protein conjugates |
US7659092B2 (en) * | 2004-12-01 | 2010-02-09 | Syntaxin, Ltd. | Fusion proteins |
US8603779B2 (en) | 2004-12-01 | 2013-12-10 | Syntaxin, Ltd. | Non-cytotoxic protein conjugates |
GB0426397D0 (en) | 2004-12-01 | 2005-01-05 | Health Prot Agency | Fusion proteins |
GB0426394D0 (en) * | 2004-12-01 | 2005-01-05 | Health Prot Agency | Fusion proteins |
US8399400B2 (en) * | 2004-12-01 | 2013-03-19 | Syntaxin, Ltd. | Fusion proteins |
US8512984B2 (en) | 2004-12-01 | 2013-08-20 | Syntaxin, Ltd. | Non-cytotoxic protein conjugates |
US8021859B2 (en) | 2005-03-15 | 2011-09-20 | Allergan, Inc. | Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells |
EP1871789B1 (de) | 2005-03-15 | 2013-11-06 | Allergan, Inc. | Modifizierte clostridiale toxine mit geänderten targeting-fähigkeiten für die target-zellen von clostridialem toxin |
AU2007347781B2 (en) | 2006-07-11 | 2013-10-03 | Allergan, Inc. | Modified clostridial toxins with enhanced translocation capability and enhanced targeting activity |
WO2008008803A2 (en) | 2006-07-11 | 2008-01-17 | Allergan, Inc. | Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells |
EP2310028B1 (de) * | 2008-06-12 | 2016-11-16 | Ipsen Bioinnovation Limited | Fusionsproteine zur Verwendung bei der Behandlung von Akromegalie |
CN107446053A (zh) | 2008-06-12 | 2017-12-08 | 益普生生物创新有限公司 | 癌症的抑制 |
US8796216B2 (en) | 2008-06-12 | 2014-08-05 | Syntaxin Limited | Suppression of neuroendocrine diseases |
GB0820970D0 (en) | 2008-11-17 | 2008-12-24 | Syntaxin Ltd | Suppression of cancer |
US9623117B2 (en) * | 2011-04-04 | 2017-04-18 | Wisconsin Alumni Research Foundation | Method for selective targeting and entry of bacterial toxins to cells |
GB201219024D0 (en) | 2012-10-23 | 2012-12-05 | Syntaxin Ltd | Assay |
GB201312317D0 (en) | 2013-07-09 | 2013-08-21 | Syntaxin Ltd | Cationic neurotoxins |
WO2016110662A1 (en) | 2015-01-09 | 2016-07-14 | Ipsen Bioinnovation Limited | Cationic neurotoxins |
GB201517450D0 (en) | 2015-10-02 | 2015-11-18 | Ipsen Biopharm Ltd | Method |
EP3263710A1 (de) | 2016-07-01 | 2018-01-03 | Ipsen Biopharm Limited | Herstellung von aktivierten clostridien-neurotoxinen |
JP7186228B2 (ja) | 2018-02-26 | 2022-12-08 | イプセン バイオファーム リミテッド | 非細胞毒性プロテアーゼの注入を案内するための超音波の使用 |
US11975055B2 (en) | 2018-05-21 | 2024-05-07 | Ipsen Biopharm Limited | Suppression of bone cancer-induced allodynia |
GB201815817D0 (en) | 2018-09-28 | 2018-11-14 | Ispen Biopharm Ltd | Clostridial neurotoxins comprising and exogenous activation loop |
US20220016221A1 (en) | 2018-12-05 | 2022-01-20 | Ipsen Biopharm Limited | Treatment of symptoms of traumatic brain injury |
GB201900621D0 (en) | 2019-01-16 | 2019-03-06 | Ipsen Biopharm Ltd | Labelled polypeptides |
GB201914034D0 (en) | 2019-09-30 | 2019-11-13 | Ipsen Biopharm Ltd | Treatment of neurological disorders |
GB202100566D0 (en) | 2021-01-15 | 2021-03-03 | Ipsen Biopharm Ltd | Treatment of brain damage |
GB202104294D0 (en) | 2021-03-26 | 2021-05-12 | Ipsen Biopharm Ltd | Clostridial neurotoxins comprising an exogenous activation loop |
EP4313120A1 (de) | 2021-03-30 | 2024-02-07 | Ipsen Biopharm Limited | Behandlung von schmerzen und entzündlichen erkrankungen |
KR20230155007A (ko) | 2021-03-30 | 2023-11-09 | 입센 바이오팜 리미티드 | 통증 & 염증성 장애의 치료를 위한 촉매 불활성 클로스트리디움 신경독소 |
GB202116795D0 (en) | 2021-11-22 | 2022-01-05 | Ipsen Biopharm Ltd | Treatment of visceral pain |
GB202214232D0 (en) | 2022-09-28 | 2022-11-09 | Ispen Biopharm Ltd | Clostridial neurotoxins comprising an activating exogenous protease cleavage site |
GB202214229D0 (en) | 2022-09-28 | 2022-11-09 | Ipsen Biopharm Ltd | Clostridial neurotoxins comprising an activating endosomal protease cleavage site |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4664911A (en) * | 1983-06-21 | 1987-05-12 | Board Of Regents, University Of Texas System | Immunotoxin conjugates employing toxin B chain moieties |
US5668255A (en) * | 1984-06-07 | 1997-09-16 | Seragen, Inc. | Hybrid molecules having translocation region and cell-binding region |
EP0329184A3 (de) * | 1988-02-19 | 1990-05-23 | Neorx Corporation | Antimere und antimere Konjugation |
US5045451A (en) * | 1988-10-26 | 1991-09-03 | Board Of Regents | Methods for screening antibodies for use as immunotoxins |
WO1990010692A1 (en) * | 1989-03-15 | 1990-09-20 | University Of Florida | Monoclonal antibody for use in detection and treatment of childhood leukemia |
US5300496A (en) * | 1991-09-30 | 1994-04-05 | The University Of British Columbia | Complexed vanadium for the treatment of diabetes mellitus |
US5877295A (en) * | 1992-09-30 | 1999-03-02 | The Center For Blood Research | Antibodies which bind a subpopulation of Mac-1 (CD11b/CD18) molecules which mediate neutrophil adhesion to ICAM-1 and fibrinogen |
GB9305735D0 (en) * | 1993-03-19 | 1993-05-05 | North John R | Novel agent for controlling cell activity |
-
1993
- 1993-03-19 GB GB939305735A patent/GB9305735D0/en active Pending
-
1994
- 1994-03-18 EP EP94909262A patent/EP0689459B1/de not_active Expired - Lifetime
- 1994-03-18 WO PCT/GB1994/000558 patent/WO1994021300A2/en active IP Right Grant
- 1994-03-18 NZ NZ262484A patent/NZ262484A/en unknown
- 1994-03-18 BR BR9406232A patent/BR9406232A/pt not_active Application Discontinuation
- 1994-03-18 PL PL94310698A patent/PL178895B1/pl unknown
- 1994-03-18 ES ES94909262T patent/ES2183836T3/es not_active Expired - Lifetime
- 1994-03-18 DE DE69431832T patent/DE69431832T2/de not_active Expired - Lifetime
- 1994-03-18 AU AU62175/94A patent/AU671203C/en not_active Expired
- 1994-03-18 JP JP52080694A patent/JP4300265B2/ja not_active Expired - Lifetime
- 1994-03-18 CN CNB941921255A patent/CN1195551C/zh not_active Expired - Fee Related
- 1994-03-18 SG SG1996007056A patent/SG73411A1/en unknown
- 1994-03-18 DK DK94909262T patent/DK0689459T3/da active
- 1994-03-18 KR KR1019950703985A patent/KR960700756A/ko not_active Application Discontinuation
- 1994-03-18 AT AT94909262T patent/ATE228856T1/de not_active IP Right Cessation
- 1994-03-18 CA CA002158647A patent/CA2158647A1/en not_active Abandoned
- 1994-03-18 PT PT94909262T patent/PT689459E/pt unknown
- 1994-03-18 CZ CZ952426A patent/CZ242695A3/cs unknown
- 1994-03-18 HU HU9502673A patent/HU217220B/hu not_active IP Right Cessation
- 1994-03-18 SK SK1155-95A patent/SK115595A3/sk unknown
- 1994-03-20 IL IL10904594A patent/IL109045A0/xx unknown
- 1994-03-21 IN IN200MA1994 patent/IN178499B/en unknown
-
1995
- 1995-09-15 NO NO953643A patent/NO953643L/no not_active Application Discontinuation
- 1995-09-18 FI FI954390A patent/FI954390A/fi unknown
-
2007
- 2007-06-28 US US11/819,647 patent/US20080070278A1/en not_active Abandoned
- 2007-08-15 JP JP2007211720A patent/JP4740206B2/ja not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE228856T1 (de) | Mittel für die steuerung von der zellaktivität | |
PT826051E (pt) | Derivados de toxina botulinica capazes de modificar funcoes aferentes sensoriaisperifericas | |
DE69435307D1 (de) | Bazillus Thuringiensis und dessen insektizide Proteine | |
BR9815518A (pt) | Agentes antibacterianos de oxazolidinona tendo funcionalidade de tiocarbonila | |
ATE291923T1 (de) | Veränderter faktor viii | |
NO964966D0 (no) | Lactobacillusstammer av human opprinnelse, blandinger samt anvendelse derav | |
ATE177114T1 (de) | Polypeptide und daraus hergestellte, gegen hiv wirksame substanzen | |
ES2139740T3 (es) | Cola de fibrina de dos componentes. | |
MX9304070A (es) | Piperidilamidas, piperidilsulfonamidas y piperidilsulfoxamidas novedosas como inhibidores de la biosintesis del colesterol. | |
KR910700067A (ko) | 항 hiv제 | |
DK0633928T3 (da) | Mikroorganismer, deres fremstilling og anvendelse | |
DE69838615D1 (de) | ppGpp-SYNTHETASE UND EXPRESSIONSSYSTEME ZUR VERBESSERTEN HERSTELLUNG VON PROTEINEN | |
NO960710D0 (no) | Nye tripeptider nyttige i immun- og CNS-terapi | |
DE59808166D1 (de) | Verwendung von 2-methyl-thiazolidin-2,4-dicarbonsäure als mukolytikum | |
ATE171072T1 (de) | Rezeptor-konjugate zum targeting von arzneiwirkstoffen und anderen wirksubstanzen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 0689459 Country of ref document: EP |
|
EEIH | Change in the person of patent owner | ||
REN | Ceased due to non-payment of the annual fee |